Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE: 688513)
Health Care · Pharmaceuticals · CN
CN¥45.56
-8.29% today · -35.5% 1Y
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE: 688513) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.18B and employs 1,480 people.
Over the last twelve months the share price has lost 35.5%, trading between 40.25 and 80.48.
Tweenvest scores Chengdu Easton Biopharmaceuticals Co., Ltd. across four factors: quality 75/100, value 32/100, growth 56/100, dividend 21/100. Its strongest factor is quality.
688513 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.18B
- Revenue (TTM)
- $196.66M
- P/E
- 28.47
- EPS
- 1.60
- Dividend yield
- 1.08%
- Beta (5Y)
- 0.04
- 52-week high
- CN¥80.48
- 52-week low
- CN¥40.25
- Avg volume (3M)
- —
- Shares outstanding
- 174.35M
- Employees
- 1,480
- Next earnings
- —
About Chengdu Easton Biopharmaceuticals Co., Ltd.
Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the full spectrum of drug development, encompassing research, development, production, and market distribution of medicinal products. The company offers finished medications tailored for various medical disciplines, including pain management (anesthetics/analgesics), cardiovascular health, oncology, and pediatrics. Beyond ready-to-use drugs, it also manufactures active pharmaceutical ingredients (APIs) for a broader range of therapeutic areas, such as cancer treatment, heart conditions, pain relief, anti-inflammatory uses, gastrointestinal issues, antiemetics, neurological and psychiatric disorders, and urinary system ailments. Established in 2009, the firm is headquartered in Chengdu, China.
- ISIN
- CNE100004397
- Founded
- 2009
- Listed since
- Sep 2, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,192.07 | -3.37% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.44 | -0.99% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.50 | -1.89% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.90 | -1.04% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.60 | -1.73% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.